仿制药索磷布韦与达拉他韦固定剂量复方片治疗1361例丙型肝炎1、2、3、4基因型患者:高持续病毒学应答率的多中心III期临床试验
该多中心III期试验在46个中心纳入1361例丙型肝炎患者,使用索磷布韦400mg与达拉他韦60mg的仿制药固定剂量复方片,按现行指南给予12或24周疗程(联合或不联合利巴韦林)。意向性治疗和符合方案分析的SVR12率分别为94.7%和98.8%,安全性无异常,单表片剂依从性极佳。结论认为该低成本方案适合资源有限国家的丙肝消除项目。
要点
- 仿制索磷布韦/达拉他韦固定剂量复方片治疗丙肝的意向性治疗SVR12率为94.7%。
- 符合方案分析的SVR12率达98.8%,安全性无异常且单表片剂依从性极佳。
- 该方案每人费用低于100美元,适合资源有限国家的丙肝消除项目。
核心结论
- 仿制索磷布韦与达拉他韦固定剂量复方片治疗丙肝获得高SVR12率,与其他泛基因型方案的III期试验结果相当。
- 该方案在代表性真实世界人群中以类似规模开展,每人费用低于100美元,适合资源有限国家的消除项目。
研究设计与样本
- 多中心III期临床试验,从46个中心招募1361例丙型肝炎患者。
- 索磷布韦400mg与达拉他韦60mg共配制为固定剂量复方片(Sovodak, Rojan Pharma, Tehran, Iran)。
- 按现行指南给予12或24周疗程,联合或不联合利巴韦林。
- 治疗结束后12周评估持续病毒学应答(SVR12)。
主要发现
- 总体患者中女性占21%,平均年龄50岁;39%为肝硬化,22%有治疗经验。
- 基因型分布:1型47%,3型41%,其他基因型2%,基因型未知10%。
- 意向性治疗和符合方案分析的SVR12率分别为94.7%和98.8%。
- 安全性无异常,治疗耐受良好,单表片剂依从性极佳。
关键数值与推荐
- 索磷布韦剂量为400mg,达拉他韦剂量为60mg,共配制为固定剂量复方片。
- 疗程为12或24周,联合或不联合利巴韦林,按现行指南执行。
- SVR12定义为治疗结束后12周评估的持续病毒学应答。
临床怎么用
- 在资源有限国家,可考虑使用仿制索磷布韦/达拉他韦固定剂量复方片作为丙肝的泛基因型治疗方案。
- 该方案每人费用低于100美元,适合用于丙肝消除项目的大规模治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of sofosbuvir and daclatasvir is a potent, pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited countries where newer, expensive combinations are not available. This combination has been widely tested on genotype 4. However, Phase III trials of this combination in other genotypes have been cost prohibitive. With the introduction of generic, low-cost sofosbuvir and daclatasvir, large-scale studies in resource-limited countries are now possible. METHODS: Sofosbuvir at 400 mg and daclatasvir at 60 mg were coformulated into a fixed-dose combination (FDC) tablet (Sovodak, Rojan Pharma, Tehran, Iran). Patients from 46 centers were dosed for 12 or 24 weeks with or without ribavirin, in line with existing guidelines. Responses to treatment were evaluated 12 weeks after the end of treatment (for a sustained virological response at Week 12; SVR12). RESULTS: There were 1361 patients recruited. Overall, the patients were 21% female, with a mean age of 50 years; 39% were cirrhotic; 22% were treatment-experienced; 47% were genotype 1, 41% were genotype 3, and 2% were other genotypes. The genotype was not known in 10% of the patients. The intention-to-treat and per-protocol SVR12 rates were 94.7% and 98.8%, respectively. The safety profile was unremarkable, treatment was well tolerated, and compliance with the single-tablet regimen was excellent. CONCLUSIONS: The treatment with FDC of sofosbuvir and daclatasvir achieved high SVR12 rates, equivalent to those seen in Phase III trials of other pangenotypic options, and has been conducted at a similar scale in a representative, real-world population at a cost of under $100 per patient, which makes this combination suitable for elimination protocols in resource-limited countries. CLINICAL TRIALS REGISTRATION: NCT03200184.
引用
- Merat S. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis. 2020. PMID: 31504303. doi:10.1093/cid/ciz628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。